Printer Friendly

CYTOGEN AND CYTORAD REPORT FAVORABLE RESULTS IN PROSTATE CANCER IMAGING

 PRINCETON, N.J., Dec. 7 /PRNewswire/ -- CYTOGEN Corporation (NASDAQ: CYTO) and CYTORAD Incorporated (NASDAQ: CYTDZ) reported clinical data showing the utility of OncoScint(R) Prostate, a monoclonal antibody-based imaging agent, in the preoperative evaluation of patients with prostate cancer.
 At the 79th Scientific Assembly and Annual Meeting of the Radiologic Society of North America in Chicago, Dr. Donald A. Podoloff, of M.D. Anderson Cancer Center, presented clinical trial results in which OncoScint Prostate correctly identified regional lymph node involvement in 11 of 21 patients with metastatic prostate cancer. Podoloff states, "These results indicate that OncoScint Prostate provides the clinician with useful information regarding the status of the patient's lymph nodes prior to staging pelvic lymphadenectomy and radical prostatectomy." Podoloff further explained, "The OncoScint Prostate scan is more sensitive than CT in evaluating pre-surgical patients." OncoScint Prostate also correctly identified forty-two of forty-four patients with negative lymph nodes.
 Also at the Radiologic Society meeting, Dr. Charles Neal, of the Memorial Medical Center in Springfield, Illinois, presented results which showed that in comparative studies with CT and MRI, OncoScint Prostate offered improved ability to non-invasively evaluate prostate cancer patients scheduled to undergo staging pelvic lymph node dissection. Neal explains, "In these studies, CT and MRI are limited in their ability to accurately assess the presence of prostate cancer metastases when the pelvic nodes are not enlarged beyond 1.2 to 1.5 cm. OncoScint Prostate has been able to correctly identify pelvic lymph node metastases as small as 0.5 cm."
 OncoScint Prostate is currently in Phase III human clinical studies and is expected to be the subject of a Product License Application to the Food and Drug Administration in 1994. The American Cancer Society estimates that 165,000 new cases of prostate cancer will occur in the United States during 1993, and approximately 35,000 men will die from the disease. Prostate cancer is the most common cancer, as well as the second leading cause of cancer deaths, in men.
 CYTOGEN is a biopharmaceutical company engaged in the marketing and development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 CYTORAD is a public corporation which, through CYTOGEN, engages in the research and development of proprietary antibody-based delivery systems for diagnosis and treatment of specific cancers.
 /delval/
 -0- 12/7/93
 /CONTACT: T. Jerome Madison, vice president of Finance of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation; CYTORAD Incorporated ST: New Jersey IN: MTC SU:

JM -- PH018 -- 1385 12/07/93 15:24 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993
Words:440
Previous Article:ALTA ACQUIRES FULL OWNERSHIP OF SOCORRO PROPERTIES
Next Article:BG&E RECEIVES 28 BIDS FROM INDEPENDENT POWER PRODUCERS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters